ArticleClinicoEconomics and outcomes research : CEOR2018

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Elena Galve-Calvo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.